Related Experiment Videos
Stroke prevention in women: role of aspirin versus ticlopidine
1Department of Neurology, State University of New York, Buffalo.
Insights
Ticlopidine and aspirin are antiplatelet drugs that reduce recurrent stroke risk. Ticlopidine shows equal benefit for men and women, unlike aspirin, with similar side effects.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Stroke is a leading cause of death in North America.
- Women and men have similar initial stroke risks but differ in recurrent stroke rates.
- Antiplatelet drugs like aspirin and ticlopidine are crucial for secondary stroke prevention.
Purpose of the Study:
- To compare the efficacy and safety of aspirin and ticlopidine in stroke prevention.
- To determine if stroke prevention benefits differ between men and women for these antiplatelet agents.
- To highlight effective stroke prevention strategies for both genders.
Main Methods:
- Review of major stroke prevention trials.
- Comparative analysis of aspirin and ticlopidine efficacy in men versus women.
- Assessment of adverse event incidence for both drugs.
Main Results:
- Aspirin demonstrated variable effectiveness between sexes in some trials.
- Ticlopidine showed consistent benefits for stroke prevention in both men and women.
- Ticlopidine's adverse effect profile was comparable to aspirin's.
Conclusions:
- Ticlopidine offers a reliable option for stroke prevention in both men and women.
- Both aspirin and ticlopidine are effective in reducing recurrent stroke risk.
- Gender-specific considerations may influence antiplatelet therapy choice for stroke prevention.
Abstract:
Stroke is the third leading cause of death in North America. Most studies indicate that women are just as likely as men to have an initial stroke but less likely to have a recurrent stroke. Aspirin and ticlopidine are two antiplatelet drugs that reduce the risk of recurrent stroke by 25% to 30%. In some stroke prevention trials, aspirin has been shown to be more effective for men than for women. In contrast, major stroke prevention trials using ticlopidine have demonstrated equal benefit in women and in men. The overall incidence of adverse effects seen with ticlopidine is not significantly different from that observed with aspirin. There are now two effective agents useful in stroke prevention in both men and women.